Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
and hospitalization in infants under 1 year of age and there is currently no market-approved …

Antibodies can impact pathogens in the presence or in the absence of effector cells or
effector molecules such as complement, and experiments can often sort out with precision …

Glycosylation of the immunoglobulin G (IgG)-Fc tail is required for binding to Fc-gamma
receptors (FcγRs) and complement-component C1q. A variety of IgG1-glycoforms is …

Broadly neutralizing antibodies (bNAbs) against HIV-1 provide both effective pre-exposure
prophylaxis and treatment of HIV-1 infection in murine and nonhuman primate models …

Combination antiretroviral therapy (ART) can block multiple stages of the HIV-1 life cycle to
prevent progression to AIDS in people living with HIV-1. However, owing to the persistence …

Neutralizing antibodies (NAbs) can be both sufficient and necessary for protection against
viral infections, although they sometimes act in concert with cellular immunity. Successful …

Given the widespread use of antibodies of the immunoglobulin G (IgG) class as cytotoxic,
immunomodulatory, and neutralizing agents in the therapy of malignant, infectious, and …

Plants have emerged as commercially relevant production systems for pharmaceutical and
nonpharmaceutical products. Currently, the commercially available nonpharmaceutical …

Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been
made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are …

Protein glycosylation has a huge impact on biological processes in all domains of life. The
type of glycan present on a recombinant glycoprotein depends on protein intrinsic features …